Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial
Duncan Porter, Jurgen van Melckebeke, James Dale, C Martina Messow, Alexander McConnachie, Andrew Walker, Robin Munro, John McLaren, Euan McRorie, Jon Packham, Christopher Buckley, John Harvie, Peter Taylor, Ernest Choy, Constantino Pitzalis, Iain B McInnes
Research output: Contribution to journal › Article › peer-review
69Citations
(Scopus)
186Downloads
(Pure)
Fingerprint
Dive into the research topics of 'Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial'. Together they form a unique fingerprint.